Drug intelligence / Profile preview

NP-015

Development stage: Unknown
Lead developer: Emergent BioSolutions
Modality: Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Administration: Intravenous

Overview

NP-015, also known as Anthrax Immune Globulin Intravenous (Human) or by the brand name Anthrasil, is a biologic developed by Emergent BioSolutions. It is a hyperimmune globulin containing polyclonal immunoglobulin G (IgG) antibodies derived from the plasma of healthy donors who have been immunized with anthrax vaccine. These antibodies provide passive immunity by neutralizing anthrax toxin. It is indicated for the treatment of inhalational anthrax in adult and pediatric patients, in combination with appropriate antibacterial drugs.

Brand names: Anthrasil
Other names: Anthrax Immune Globulin Intravenous (Human)Anthrax Immune Globulin (Human)AIGIV

Targets

PA (Influenza polymerase acidic protein)

Beyond the preview

Go deeper on NP-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP-015.

Explore the full profile